UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 17 May 2024, London UK
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION
DISTRIBUTION OR FORWARDING, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN
PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE
REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH SUCH
PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE
UNLAWFUL.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN
OFFER OF SECURITIES IN ANY JURISDICTION.
GSK completes sale of remaining shares in Haleon
GSK plc (LSE/NYSE: GSK) today announced that, further to its
announcement on 16 May 2024, GSK has agreed to sell 385,320,110
ordinary shares in Haleon plc ("Haleon") at a price of 324 pence per share (the
"Placing
Shares"), raising gross
proceeds of approximately £1,248m (the "Placing").
Following settlement of the Placing, GSK will have fully exited its
position and will no longer hold any ordinary shares in
Haleon.
Following the successful demerger and premium listing of Haleon as
announced on 18 July 2022, GSK initially retained a 12.94% stake in
Haleon. As a result of the disposals announced on 12 May 2023, 6
October 2023, 16 January 2024 and 16 May 2024, GSK has since sold a
total of 1,195m ordinary shares in Haleon for cumulative gross
proceeds of approximately £3.9bn. GSK's exit of its position
in Haleon is consistent with its previous commitments to monetise
its holding in a disciplined manner.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
GSK enquiries
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Simon Moore / Dan Smith / Sarah Clements
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
Alison Hunt
|
+1 540 742 3391
|
(Washington DC)
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
Disclaimer
The contents of this announcement have been prepared by and are the
sole responsibility of GSK.
This announcement is for information purposes only and is not
intended to and does not constitute or form part of any offer or
invitation to purchase, otherwise acquire, subscribe for, sell,
otherwise dispose of or issue, or any solicitation of any offer to
sell, otherwise dispose of, issue, purchase, otherwise acquire or
subscribe for, any security.
Information regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors' in the Company's Annual Report on Form 20-F for 2023
and GSK's Q1 Results for 2024.
This Announcement does not constitute a recommendation to acquire
any ordinary shares in Haleon. This Announcement does not identify
or suggest, or purport to identify or suggest, the risks (direct or
indirect) that may be associated with an investment in Haleon. Any
investment must be made solely on the basis of publicly available
information, which has not been independently verified by Goldman
Sachs International ("Goldman
Sachs") or Merrill Lynch
International ("BofA
Securities").
No offer
Neither this announcement nor anything contained herein shall form
the basis of, or be relied upon in connection with, any offer or
purchase whatsoever in any jurisdiction and shall not constitute or
form part of an offer to sell or the solicitation of an offer to
buy any securities in the United States or in any other
jurisdiction. The securities referred to herein may not be offered
or sold in the United States absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the
"Securities
Act"). The securities referred
to herein may not be deposited in an unrestricted depositary
receipt facility for 40 days following the commencement of the
Offering or for so long as the securities are "restricted
securities" within the meaning of Rule 144 under the Securities
Act. GSK does not intend to register any part of the Offering in
the United States or to conduct a public offering in the United
States of the shares to which this announcement
relates.
This announcement does not constitute a prospectus or an offer or
invitation to purchase securities. This announcement is only
addressed to, and directed at, persons who are "qualified
investors", being persons falling within the meaning of Article
2(e) of Regulation (EU) 2017/1129 as it forms part of domestic law
in the United Kingdom by virtue of the European Union (Withdrawal)
Act 2018 and who: (a) (i) have professional experience in matters
relating to investments falling within the definition of
"investment professionals" in article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005, as
amended (the "Order"); or (ii) are persons falling within article
49(2)(a) to (d) ("high net worth companies, unincorporated
associations, etc") of the Order; or (b) persons to whom it may
otherwise lawfully be communicated, (each such persons in (a) and
(b) together being referred to as "Relevant
Persons").
In addition, this announcement is not being distributed, nor has it
been approved for the purposes of Section 21 of the Financial
Services and Markets Act 2000 ("FSMA"), by a person authorised under
FSMA.
This document is directed only at Relevant Persons and must not be
acted on or relied on by persons who are not Relevant Persons.
Under no circumstances should persons who are not Relevant Persons
rely or act upon the contents of this announcement. Any investment
or investment activity to which this announcement relates in the
United Kingdom is available only to, and will be engaged only with,
Relevant Persons. Persons distributing this announcement must
satisfy themselves that it is lawful to do so.
The Placing and the distribution of this announcement and other
information in connection with the Placing in certain jurisdictions
may be restricted by law. No action has been taken that would
permit the Placing or distribution of this announcement in any
jurisdiction where action for such purpose is required. Persons
into whose possession any document or other information referred to
herein comes should inform themselves about and observe any such
restriction. Any failure to comply with these restrictions may
constitute a violation of the securities laws of any such
jurisdiction.
In connection with the Placing, Goldman Sachs, BofA Securities and
their respective affiliates may take up a portion of the Placing
Shares as a principal position at any stage at their sole
discretion, inter alia, to take account of the objectives of GSK,
MiFID II/ UK MiFID II requirements and in accordance with
allocation policies and in that capacity may retain, purchase,
sell, offer to sell for their own accounts such Placing Shares and
other securities of the Company or related investments in
connection with the Placing or otherwise. Accordingly,
references in this announcement to the Placing Shares being sold,
offered, subscribed, acquired, placed or otherwise dealt in should
be read as including any issue or offer to, or subscription,
acquisition, placing or dealing by, Goldman Sachs, BofA Securities
or their respective affiliates acting in such capacity. In
addition, Goldman Sachs, BofA Securities and their respective
affiliates may enter into financing arrangements (including swaps
or contracts for differences) with investors in connection with
which Goldman Sachs, BofA Securities and their respective
affiliates may from time to time acquire, hold or dispose of
Placing Shares. Neither Goldman Sachs nor BofA Securities intends
to disclose the extent of any such investment or transactions
otherwise than in accordance with any legal or regulatory
obligations to do so.
Any communications that a transaction is or that the book is
"covered" (i.e. indicated demand from investors in the book equals
or exceeds the amount of the securities being offered) is not any
indication or assurance that the book will remain covered or that
the transaction and securities will be fully distributed by Goldman
Sachs or BofA Securities.
None of Goldman Sachs, BofA Securities or any of their or their
respective affiliates' directors, officers, employees, advisers or
agents accepts any responsibility or liability whatsoever for or
makes any representation or warranty, express or implied, as to the
truth, accuracy or completeness of the information in this
announcement (or whether any information has been omitted from the
announcement) or any other information relating to Haleon, GSK,
their respective subsidiaries or associated companies, whether
written, oral or in a visual or electronic form, and howsoever
transmitted or made available or for any loss howsoever arising
from any use of this announcement or its contents or otherwise
arising in connection therewith.
Goldman Sachs and BofA Securities are each authorised by the
Prudential Regulatory Authority and regulated in the United Kingdom
by the Prudential Regulation Authority and the Financial Conduct
Authority, and are acting for GSK and for no one else in connection
with the Placing and will not be responsible to anyone other than
GSK for providing the protections afforded to their customers or
for affording advice in relation to the Placing, the contents of
this announcement or any transaction, arrangement or other matter
referred to in this announcement.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: May
17, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From May 2024 to Jun 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jun 2023 to Jun 2024